Literature DB >> 19717560

A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2.

Jimmy Donkor1, Peixiang Zhang, Samantha Wong, Lauren O'Loughlin, Jay Dewald, Bernard P C Kok, David N Brindley, Karen Reue.   

Abstract

Mammalian lipins (lipin-1, lipin-2, and lipin-3) are Mg2+-dependent phosphatidate phosphatase (PAP) enzymes, which catalyze a key reaction in glycerolipid biosynthesis. Lipin-1 also functions as a transcriptional coactivator in conjunction with members of the peroxisome proliferator-activated receptor family. An S734L mutation in LPIN2 causes Majeed syndrome, a human inflammatory disorder characterized by recurrent osteomyelitis, fever, dyserythropoietic anemia, and cutaneous inflammation. Here we demonstrate that mutation of the equivalent serine in mouse lipin-1 and lipin-2 to leucine or aspartate abolishes PAP activity but does not impair lipin association with microsomal membranes, the major site of glycerolipid synthesis. We also determined that lipin-2 has transcriptional coactivator activity for peroxisome proliferator-activated receptor-response elements similar to lipin-1 and that this activity is not affected by mutating the conserved serine. Therefore, our results indicate that the symptoms of the Majeed syndrome result from a loss of lipin-2 PAP activity. To characterize sites of lipin-2 action, we detected lipin-2 expression by in situ hybridization on whole mouse sections and by quantitative PCR of tissues relevant to Majeed syndrome. Lipin-2 was most prominently expressed in liver, where levels were much higher than lipin-1, and also in kidney, lung, gastrointestinal tract, and specific regions of the brain. Lipin-2 was also expressed in circulating red blood cells and sites of lymphopoiesis (bone marrow, thymus, and spleen). These results raise the possibility that the loss of lipin-2 PAP activity in erythrocytes and lymphocytes may contribute to the anemia and inflammation phenotypes observed in Majeed syndrome patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717560      PMCID: PMC2785625          DOI: 10.1074/jbc.M109.023663

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Characterization and assay of phosphatidate phosphatase.

Authors:  A Martin; A Gomez-Muñoz; Z Jamal; D N Brindley
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome).

Authors:  P J Ferguson; S Chen; M K Tayeh; L Ochoa; S M Leal; A Pelet; A Munnich; S Lyonnet; H A Majeed; H El-Shanti
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  Characterization of the peripheral neuropathy in neonatal and adult mice that are homozygous for the fatty liver dystrophy (fld) mutation.

Authors:  C A Langner; E H Birkenmeier; K A Roth; R T Bronson; J I Gordon
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

4.  Regulation of the translocation of phosphatidate phosphohydrolase between the cytosol and the endoplasmic reticulum of rat liver. Effects of unsaturated fatty acids, spermine, nucleotides, albumin and chlorpromazine.

Authors:  R Hopewell; P Martin-Sanz; A Martin; J Saxton; D N Brindley
Journal:  Biochem J       Date:  1985-12-01       Impact factor: 3.857

5.  Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene.

Authors:  K Reue; P Xu; X P Wang; B G Slavin
Journal:  J Lipid Res       Date:  2000-07       Impact factor: 5.922

6.  The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities.

Authors:  C A Langner; E H Birkenmeier; O Ben-Zeev; M C Schotz; H O Sweet; M T Davisson; J I Gordon
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

7.  Effects of okadaic acid on the activities of two distinct phosphatidate phosphohydrolases in rat hepatocytes.

Authors:  A Gomez-Muñoz; G M Hatch; A Martin; Z Jamal; D E Vance; D N Brindley
Journal:  FEBS Lett       Date:  1992-04-13       Impact factor: 4.124

Review 8.  Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphate phosphatases.

Authors:  David N Brindley; Carlos Pilquil; Meltem Sariahmetoglu; Karen Reue
Journal:  Biochim Biophys Acta       Date:  2009-02-27

Review 9.  Roles for lipid phosphate phosphatases in regulation of cellular signaling.

Authors:  Vicki A Sciorra; Andrew J Morris
Journal:  Biochim Biophys Acta       Date:  2002-05-23

10.  Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol.

Authors:  Z Jamal; A Martin; A Gomez-Muñoz; D N Brindley
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

View more
  75 in total

Review 1.  Nuclear receptor coregulators: modulators of pathology and therapeutic targets.

Authors:  David M Lonard; Bert W O'Malley
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

2.  Lipin proteins form homo- and hetero-oligomers.

Authors:  Guang-Hui Liu; Jing Qu; Anne E Carmack; Hyun Bae Kim; Chang Chen; Hongmei Ren; Andrew J Morris; Brian N Finck; Thurl E Harris
Journal:  Biochem J       Date:  2010-11-15       Impact factor: 3.857

Review 3.  Lipins: multifunctional lipid metabolism proteins.

Authors:  Lauren S Csaki; Karen Reue
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

4.  Liver-specific loss of lipin-1-mediated phosphatidic acid phosphatase activity does not mitigate intrahepatic TG accumulation in mice.

Authors:  George G Schweitzer; Zhouji Chen; Connie Gan; Kyle S McCommis; Nisreen Soufi; Roman Chrast; Mayurranjan S Mitra; Kui Yang; Richard W Gross; Brian N Finck
Journal:  J Lipid Res       Date:  2015-02-26       Impact factor: 5.922

5.  Lipin 2/3 phosphatidic acid phosphatases maintain phospholipid homeostasis to regulate chylomicron synthesis.

Authors:  Peixiang Zhang; Lauren S Csaki; Emilio Ronquillo; Lynn J Baufeld; Jason Y Lin; Alexis Gutierrez; Jennifer R Dwyer; David N Brindley; Loren G Fong; Peter Tontonoz; Stephen G Young; Karen Reue
Journal:  J Clin Invest       Date:  2018-12-03       Impact factor: 14.808

Review 6.  Mammalian lipin phosphatidic acid phosphatases in lipid synthesis and beyond: metabolic and inflammatory disorders.

Authors:  Karen Reue; Huan Wang
Journal:  J Lipid Res       Date:  2019-02-25       Impact factor: 5.922

Review 7.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Authors:  Gina A Montealegre Sanchez; Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  2013-09-21       Impact factor: 2.670

Review 8.  Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling.

Authors:  Rosalind A Coleman; Douglas G Mashek
Journal:  Chem Rev       Date:  2011-06-01       Impact factor: 60.622

9.  Lipin 2 binds phosphatidic acid by the electrostatic hydrogen bond switch mechanism independent of phosphorylation.

Authors:  James M Eaton; Sankeerth Takkellapati; Robert T Lawrence; Kelley E McQueeney; Salome Boroda; Garrett R Mullins; Samantha G Sherwood; Brian N Finck; Judit Villén; Thurl E Harris
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

10.  Mouse lipin-1 and lipin-2 cooperate to maintain glycerolipid homeostasis in liver and aging cerebellum.

Authors:  Jennifer R Dwyer; Jimmy Donkor; Peixiang Zhang; Lauren S Csaki; Laurent Vergnes; Jessica M Lee; Jay Dewald; David N Brindley; Elisa Atti; Sotirios Tetradis; Yuko Yoshinaga; Pieter J De Jong; Loren G Fong; Stephen G Young; Karen Reue
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.